Zurcher Kantonalbank (Zurich Cantonalbank) Savara Inc Transaction History
Zurcher Kantonalbank (Zurich Cantonalbank)
- $33.8 Billion
- Q1 2025
A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Savara Inc stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 60,343 shares of SVRA stock, worth $128,530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60,343
Previous 63,616
5.14%
Holding current value
$128,530
Previous $195,000
14.36%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SVRA
# of Institutions
142Shares Held
162MCall Options Held
54.8KPut Options Held
4.1K-
Nea Management Company, LLC Timonium, MD24.5MShares$52.1 Million6.43% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$37.5 Million16.36% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$26.3 Million8.25% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$24.4 Million2.0% of portfolio
-
Vestal Point Capital, LP New York, NY11MShares$23.4 Million2.18% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $243M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.